White Paper

The Rise Of Decentralized Clinical Trials

Source: Medable
What Motivates Patients To Participate In Multiple Clinical Trials?

At the turn of the 21st century, the life sciences industry began to envision a different way to conduct clinical trials. The rise of technology such as electronic data capture (EDC) helped pave the way for the first electronic clinical trial systems. And in the coming years, electronic clinical outcome assessments (eCOA) and electronic informed consent (eConsent) would be pioneered across the industry for the first time.

In 2011, Pfizer took the first step toward decentralization, conducting the first-ever “virtual” clinical trial.

Now, in 2021, the era of decentralization is truly here. A late 2020 survey by Oracle Life Sciences highlights that we’re at the tipping point, with 76 percent of surveyed trial organizations investing in a shift to decentralized clinical trials (DCTs).

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene